Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension
- PMID: 31151956
- DOI: 10.1183/13993003.01965-2018
Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension
Abstract
Rare variants in the T-box transcription factor 4 gene (TBX4) have recently been recognised as an emerging cause of paediatric pulmonary hypertension (PH). Their pathophysiology and contribution to persistent pulmonary hypertension in neonates (PPHN) are unknown. We sought to define the spectrum of clinical manifestations and histopathology associated with TBX4 variants in neonates and children with PH.We assessed clinical data and lung tissue in 19 children with PH, including PPHN, carrying TBX4 rare variants identified by next-generation sequencing and copy number variation arrays.Variants included six 17q23 deletions encompassing the entire TBX4 locus and neighbouring genes, and 12 likely damaging mutations. 10 infants presented with neonatal hypoxic respiratory failure and PPHN, and were subsequently discharged home. PH was diagnosed later in infancy or childhood. Three children died and two required lung transplantation. Associated anomalies included patent ductus arteriosus, septal defects, foot anomalies and developmental disability, the latter with a higher prevalence in deletion carriers. Histology in seven infants showed abnormal distal lung development and pulmonary hypertensive remodelling.TBX4 mutations and 17q23 deletions underlie a new form of developmental lung disease manifesting with severe, often biphasic PH at birth and/or later in infancy and childhood, often associated with skeletal anomalies, cardiac defects, neurodevelopmental disability and other anomalies.
Copyright ©ERS 2019.
Conflict of interest statement
Conflict of interest: C. Galambos has nothing to disclose. Conflict of interest: M.P. Mullen has acted as a site principal investigator on trials sponsored by United Therapeutics, Actelion, Ikaria and GSK, and received travel support from Actelion, outside the submitted work. Conflict of interest: J.T. Shieh has nothing to disclose. Conflict of interest: N. Schwerk has nothing to disclose. Conflict of interest: M.J. Kielt has nothing to disclose. Conflict of interest: N. Ullmann has nothing to disclose. Conflict of interest: R. Boldrini has nothing to disclose. Conflict of interest: I. Stucin-Gantar has nothing to disclose. Conflict of interest: C. Haass has nothing to disclose. Conflict of interest: M. Bansal has nothing to disclose. Conflict of interest: P.B. Agrawal has nothing to disclose. Conflict of interest: J. Johnson has nothing to disclose. Conflict of interest: D. Peca has nothing to disclose. Conflict of interest: C. Surace has nothing to disclose. Conflict of interest: R. Cutrera has nothing to disclose. Conflict of interest: M.W. Pauciulo has nothing to disclose. Conflict of interest: W.C. Nichols has nothing to disclose. Conflict of interest: M. Griese has nothing to disclose. Conflict of interest: D. Ivy has contracts (through the University of Colorado School of Medicine) with Actelion, Bayer, Lilly and United Therapeutics for consultancy and research studies. Conflict of interest: S.H. Abman has nothing to disclose. Conflict of interest: E.D. Austin has nothing to disclose. Conflict of interest: O. Danhaive has nothing to disclose.
Comment in
-
The ever-expanding phenotypical spectrum of human TBX4 mutations: from toe to lung.Eur Respir J. 2019 Aug 22;54(2):1901504. doi: 10.1183/13993003.01504-2019. Print 2019 Aug. Eur Respir J. 2019. PMID: 31439725 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases